List view / Grid view
The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.
Episode 3 – Cell & gene therapy with Dr Sam Wadsworth, Ultragenyx Pharmaceutical & Dr Eric Ostertag, Poseida Therapeutics
Tune in to this podcast to learn about AAV vectors for gene therapy delivery and engineering CAR T cells against solid tumours.
Treatment with Viking Therapeutics' dual agonists resulted in mean reductions in body weight of up to 27 percent compared to semaglutide-treated animals.
This whitepaper overviews phenotypic and functional characterisation of CAR-T cells with advanced flow cytometry and live-cell analysis.
Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal models, a pre-clinical study has revealed.
The discovery of a link between the human leukocyte antigen (HLA) and genital warts may lead to mRNA-based vaccines against HPV and other diseases.
A $5 million grant will be used to train students in stem cell research to contribute towards new stem cell-based therapeutics.
An interview with Dr Arun Srivastava about his research into safe and effective AAV vectors that do not prompt a reaction from the immune system.
Laboratories operating under GMP or GLP regulations must follow guidelines set by agencies to protect scientific integrity or demonstrate quality assurance of manufactured products.
Sanofi has completed the acquisition of mRNA therapeutics company Translate Bio for a total of approximately $3.2 billion.
Synthetic biology processes can be useful to therapeutic development, diagnostics and vaccine advancement. Drug Target Review’s Victoria Rees spoke with Dr Jim Collins, Termeer Professor of Medical Engineering & Science at MIT and Founding Core Faculty & Lead, Living Cellular Devices at the Wyss Institute at Harvard University, to explore…
Scientists have discovered drug targets in the neural circuits that encode memories, paving the way for the treatment of brain disorders.
SARS-CoV-2 Spike gene mutants may be developed into immunogens for new vaccines against COVID-19, a study in hamsters has shown.